ERC Advanced Grant · 2020
Targeted strategies for prevention and treatment of fibrosis-associated liver cancer
Advanced liver diseases such as cirrhosis and hepatocellular carcinoma (HCC) are major challenges for global health. HCC is the second leading and fastest rising cause of cancer death worldwide. Viral and metabolic liver disease are the main risk factors for HCC, which nearly always arises in advanced liver fibrosis. For metabolic liver disease approved therapies are absent. Cure or suppression of viral infection cannot eliminate the HCC risk in patients with advanced fibrosis. Despite significant progress, therapeutic options for established HCC are still limited in efficacy and safety. Importantly, patient survival in HCC is dependent on the underlying fibrotic liver disease which is not…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.
← All labs at National Institute of Health and Medical Research (INSERM)